Literature DB >> 2948640

Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.

B Chandrasekaran, J Dimling, R L Capizzi.   

Abstract

Mice bearing the P388/S or P388/ADR (doxorubicin-resistant) leukemia were treated with menogaril or mitoxantrone. Both drugs were highly effective against P388/S but were ineffective against the doxorubicin-resistant subline, indicating cross-resistance. These observations may be of use in the design of clinical trials with these drugs.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 2948640

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  4 in total

Review 1.  Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.

Authors:  D Faulds; J A Balfour; P Chrisp; H D Langtry
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

2.  Identification of anthracyclines and related agents that retain preferential activity over adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A.

Authors:  H M Coley; P R Twentyman; P Workman
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 3.  Mitoxantrone: a review of its pharmacological properties and use in acute nonlymphoblastic leukaemia.

Authors:  C J Dunn; K L Goa
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

4.  N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.

Authors:  R Ganapathi; D Grabowski; T W Sweatman; R Seshadri; M Israel
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.